eMed Partners with Novo Nordisk for Wegovy® Pill Accessibility
Novo Nordisk names eMed a Novocare Recognized Care Provider for first and only oral medication for weight loss
Leading digital health platform eMed has taken a significant step by earning recognition as a Novocare Recognized Care Provider from Novo Nordisk. This partnership allows eMed to offer the newly FDA-approved Wegovy® pill, marking it as the first oral medication aimed at assisting in weight management for adults. This collaboration is pivotal as it strengthens eMed's role as a responsible leader in the management of GLP-1 access, ensuring patients receive structured and consistent support in a market where results can vary considerably.
Given FDA approval received late last year, Wegovy® (oral semaglutide) now presents patients with an innovative once-daily pill that addresses the needs of individuals facing obesity or overweight challenges. eMed has developed a clinical framework to facilitate the appropriate use of Wegovy® pill, underscoring its commitment to guided medical support and fostering long-term patient engagement.
Linda Yaccarino, the CEO of eMed, emphasizes the importance of structured care: "GLP-1s are redefining health but too often, people are handed powerful medications without the structure, accountability, and medical support they deserve. eMed exists to change that. We deliver GLP-1s the way they were meant to be delivered—through a program designed to drive real, lasting outcomes. Being recognized by Novo Nordisk reinforces what we believe at our core: GLP-1s work best when care, structure, and accountability come first."
According to Dave Moore, Executive Vice President, U.S. Operations of Novo Nordisk Inc., it is crucial to have access to FDA-approved treatments like Wegovy® pill through quality programs that ensure proper use and continuous support. “Our partnership with eMed reflects our confidence in their ability to deliver care the right way—combining access and consistent medical guidance to drive safe, meaningful, and sustained use,” he said.
Through eMed's streamlined platform, members can conveniently access the Wegovy® pill, a non-injection option that seamlessly integrates into daily routines while maintaining effectiveness. In clinical studies conducted by Novo Nordisk, participants who adhered to a daily regimen of Wegovy® pill, combined with a reduced-calorie diet and exercise, reported an impressive average weight loss of around 17%.
eMed's dedication to structured, clinically informed care aims at producing long-lasting results. Initially granting access to FDA-approved GLP-1 medications such as Wegovy® pill is just the beginning of their support. The comprehensive approach includes medication, personalized clinical oversight, assistance with adherence, and a well-coordinated care pathway to promote effective ongoing management. Notably, eMed's statistics reveal that members who actively engage with its program report over 90% adherence—significantly surpassing industry standards—while an impressive 99% experience improvement in at least one health marker within just six months.
About eMed Population Health eMed Population Health stands out as a premier employer-focused platform for effectively managing GLP-1 medications. The platform is designed to aid employers in managing GLP-1 demand and healthcare expenses by verifying medical eligibility and guiding appropriate prescribing practices through a comprehensive care structure. This approach ultimately strengthens workforce health and mitigates healthcare fragmentation. For individuals, eMed offers structured clinical support to foster long-term adherence, which currently exceeds 90%. In an industry often plagued with disconnected services and inconsistent oversight, eMed provides a reliable, guided approach to GLP-1 treatment, emphasizing sustainable health instead of quick fixes. Apart from catering to employers, eMed also extends its services to consumers seeking clinically supported weight management solutions.
Frequently Asked Questions
What is the purpose of the partnership between eMed and Novo Nordisk?
The partnership aims to provide access to the Wegovy® pill as part of a clinically guided care model for effective weight management.
What is Wegovy® pill and how does it work?
The Wegovy® pill, an oral semaglutide medication, is designed to assist with weight management, offering a non-injectable alternative for those diagnosed with obesity or overweight.
Who qualifies for the Wegovy® program through eMed?
Individuals seeking weight management solutions may qualify for the Wegovy® program, contingent on appropriate medical assessments and guidelines.
How does eMed support its members?
eMed supports its members through structured clinical oversight, adherence assistance, and personalized care pathways, ensuring long-term success in weight management.
What results can members expect from using Wegovy® pill?
Evidence from clinical studies indicates that individuals using the Wegovy® pill, alongside dietary and exercise commitments, achieved significant weight loss of about 17% on average.
